<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745771</url>
  </required_header>
  <id_info>
    <org_study_id>CL-033-II-02</org_study_id>
    <nct_id>NCT00745771</nct_id>
  </id_info>
  <brief_title>Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness</brief_title>
  <official_title>Multiple Dose, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness From Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEA AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEA AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple-dose, double-blind, double-dummy, parallel, randomized, placebo and active
      controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for muscle
      soreness from exercise.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Muscle Soreness</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg Ketoprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Ketoprofen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diractin</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diractin</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understands nature and provision of the study

               -  Have been informed about the study by the investigator and gave signed and dated
                  informed consent prior to participation

               -  Muscle soreness with a pain score of at least 3 on a 10 point categorical pain
                  scale at 12-16h after exercise

               -  Male and female subjects

               -  Age 18-55 years

               -  Subjects in good health as determined by the Investigator

               -  Woman of childbearing potential using reliable methods of contraception with a
                  low failure rate (i.e. less than 1% per year), e.g. implants, injectables,
                  combined oral contraceptives, reliable intrauterine-devices, vasectomised/
                  infertile partner or surgically sterile (uterus removed or both tubes tied) or
                  postmenopausal (at least 2 years without periods)

        Exclusion Criteria:

          -  4.2.1 General Exclusion Criteria

               -  Investigator or any other team member involved directly or indirectly in the
                  conduct of the clinical trial

               -  Subjects who are inmates of psychiatric wards, prisons, or other state
                  institutions

               -  Participation in another clinical trial within the last 30 days and during the
                  study

               -  Not willing to refrain from exposing target areas after treatment to excessive
                  ultraviolet light (solar radiation or solarium)

               -  Pregnancy or lactation

        4.2.2 Medical History Related Exclusion Criteria

          -  History of dermal allergic reactions

          -  Known hypersensitivity or allergy (including photoallergy) to NSAID´s including
             ketoprofen, and ingredients used in pharmaceutical products

          -  Alcohol or drug abuse

          -  Malignancy within the past 2 years

          -  Skin lesions, dermatological diseases or tattoo in the treatment area

          -  Major surgery 3 months before enrolment

          -  NSAID idiosyncrasy

          -  Impaired haematopoesis and coagulation

          -  Gastric and duodenal ulcer and gastrointestinal bleedings

          -  Systemic lupus erythematodes, mixed connective tissue disease

          -  Major heart disease / uncontrolled hypertension

          -  Hepatic failure with ALT and/or AST &gt; 2.0 ULN

          -  Renal failure with serum creatinine levels &gt; 1.5 milligrams/deciliter (mg/dL)

          -  Varicosis, thrombophlebitis and other vascular disorders of the lower extremities

          -  Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the
             musculo-sceletal system of the lower limbs

          -  HIV - Infection

          -  Hepatitis B or C

          -  Asthma bronchiale

          -  Blood donation one month before screening and during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egbert Seidel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>X-pert Med Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>X-pert Med GmbH</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ingrid Patzak</name_title>
    <organization>IDEA AG</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>of Diractin®</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

